Shenzhen Immunofoco (2633140D HK)

Analysis

Health Care • China

Shenzhen Immunofoco Biotechnology Co., Ltd. develops innovative cell therapies. The Company produces anti-CLDN18.2 CAR-T cell therapy candidate (IMC002) for treatment of solid tumors and anti-EpCAM CAR-T cell therapy candidate (IMC001). Shenzhen Immunofoco Biotechnology conducts businesses in China.

Refresh

Focused

No publications yet

There aren’t any buy-side reports right now

Back to "All"

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00